Growth Metrics

Dna X (SONM) Net Income towards Common Stockholders (2018 - 2025)

Dna X filings provide 8 years of Net Income towards Common Stockholders readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 61.3% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.3 million, a 167.48% decrease, with the full-year FY2025 number at -$13.8 million, up 54.99% from a year prior.
  • Net Income towards Common Stockholders hit $3.5 million in Q4 2025 for Dna X, up from -$4.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $12.8 million in Q4 2022 to a low of -$11.7 million in Q4 2021.
  • Median Net Income towards Common Stockholders over the past 5 years was -$2.7 million (2024), compared with a mean of -$2.5 million.
  • The widest YoY moves for Net Income towards Common Stockholders: up 793.47% in 2024, down 1399.8% in 2024.
  • Dna X's Net Income towards Common Stockholders stood at -$11.7 million in 2021, then surged by 209.56% to $12.8 million in 2022, then plummeted by 110.02% to -$1.3 million in 2023, then skyrocketed by 793.47% to $8.9 million in 2024, then crashed by 61.3% to $3.5 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were $3.5 million (Q4 2025), -$4.8 million (Q3 2025), and -$7.5 million (Q2 2025) per Business Quant data.